Q86-89: Holding / Bridging Therapy Prior to Infusion

!Holding / Bridging Therapy
This section is currently disabled and cannot be answered.

Question 86: Did the recipient receive holding / bridging therapy prior to infusion?

Holding therapy is therapy given before the product is collected. Bridging therapy is any treatment that is given after the leukapheresis, during the period of cell manufacturing, with the goal of controlling the disease until the cellular product is ready to be infused.

Indicate if the recipient received holding or bridging therapy prior to infusion.

Question 87: Type of Holding / Bridging Therapy (check all that apply)

A recipient may receive both holding and bridging therapy prior to infusion. Select all that apply for the type of therapy received prior to infusion.

Questions 88-89: Date holding / bridging therapy started

A recipient may receive both holding and bridging therapy prior to infusion. Report the first date that the first therapy started.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Questions 90-91: Date holding / bridging therapy stopped

A recipient may receive both holding and bridging therapy prior to infusion. Report the stop date of the last therapy.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.